Related Experiment Video

Updated: Dec 31, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.3K

Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways

Wan He1, Zhijian Xu2, Dongliang Song1

  • 1Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

Life Sciences
|January 12, 2020
PubMed
Abstract

Insights

Rafoxanide effectively treats diffuse large B-cell lymphoma (DLBCL) by inhibiting cell viability and inducing apoptosis. This novel therapy shows promise for DLBCL patients with poor prognoses, reducing tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid malignancy with limited treatment options.
  • Previous research demonstrated rafoxanide's efficacy in treating multiple myeloma (MM).

Purpose of the Study:

  • To evaluate the anti-cancer effects of rafoxanide on DLBCL.
  • To elucidate the molecular mechanisms underlying rafoxanide's action in DLBCL.

Main Methods:

  • Cell viability and apoptosis assessed via CCK-8 assay and flow cytometry.
  • Western blot used to analyze protein and pathway regulation.
  • Xenograft mouse models employed for in vivo efficacy studies, with TUNEL and immunofluorescence assays.

Main Results:

  • Rafoxanide significantly inhibited DLBCL cell viability and induced apoptosis.
  • The compound caused cell cycle arrest, reduced mitochondrial membrane potential, and increased reactive oxygen species (ROS).
  • Rafoxanide modulated PTEN/PI3K/AKT and JNK/c-Jun pathways, upregulated H2AX phosphorylation, and inhibited DNA repair, leading to reduced tumor volume in vivo.

Conclusions:

  • Rafoxanide demonstrates significant anti-DLBCL activity through multiple molecular mechanisms.
  • These findings suggest rafoxanide as a potential novel therapeutic agent for DLBCL.
Keywords:
ApoptosisDNA damageDiffuse large B-cell lymphomaPTEN/PI3K/AKTRafoxanide

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K